Drug intelligence / Profile preview

Cellavita HD

Development stage: Unknown
Lead developer: Cellavita
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Cellavita HD is an investigational stem cell therapy developed for the treatment of Huntington's disease. It utilizes dental-pulp-derived mesenchymal stem cells, with the aim of restoring lost brain cells affected by the neurodegenerative process in Huntington's disease. The therapy is administered as a monthly intravenous injection over multiple cycles. Cellavita HD is being developed by Cellavita, a biotechnology company based in Brazil, and has been evaluated in phase 1 and phase 3 clinical trials for safety and efficacy in patients with Huntington's disease. As of late 2023, it had not yet received regulatory approval or announced plans to pursue FDA approval.

Brand names: cellavita hd
Other names: cellavita hd

Beyond the preview

Go deeper on Cellavita HD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellavita HD.

Explore the full profile